MORPHOLOGICAL CHARACTERISTICS IN THE TREATMENT OF MULTIDRUG-RESISTANT PULMONARY TUBERCULOSIS AND OPTIMIZATION OF TREATMENT EFFICACY

• Yitmasova T.D

  Author

• Usmonov I.H

  Author

Tuberculosis (TB) is a widespread infectious illness, with multidrug-resistant tuberculosis (MDR-TB) presenting significant treatment challenges due to resistance to first-line medications. According to the World Health Organization (WHO), around 500,000 new cases of MDR-TB are recorded each year, with treatment success rates ranging between 50-60% globally. Studying the morphological alterations in lung tissue during the progression of MDR-TB and its treatment could offer valuable insights for enhancing therapeutic strategies and improving recovery outcomes[1].

World Health Organization. (2023). Global Tuberculosis Report 2023. WHO. Retrieved from https://www.who.int/tb/publications/global_report/en/

Udwadia, Z. F., Amale, R. A., Ajbani, K. K., & Rodrigues, C. (2012). Totally drug-resistant tuberculosis in India. Clinical Infectious Diseases, 54(4), 579–581.

Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., ... & Warren, R. M. (2017). The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. The Lancet Respiratory Medicine, 5(4), 291–360.

Lange, C., Chesov, D., Heyckendorf, J., Leung, C. C., Udwadia, Z., & Dheda, K. (2018). Drug-resistant tuberculosis: An update on disease burden, diagnosis, and treatment. Respirology, 23(7), 656–673. https://doi.org/10.1111/resp.13304

Pontali, E., Raviglione, M. C., & Migliori, G. B. (2019). Regimens to treat multidrug-resistant tuberculosis: past, present, and future perspectives. European Respiratory Review, 28(152), 190035. https://doi.org/10.1183/16000617.0035-2019

Gandhi, N. R., Nunn, P., Dheda, K., Schaaf, H. S., Zignol, M., van Soolingen, D., & Bayona, J. (2018). Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. The Lancet, 391(10131), 1642–1656. https://doi.org/10.1016/S0140-6736(18)30139-3

Jenkins, H. E., Tolman, A. W., Yuen, C. M., Parr, J. B., Keshavjee, S., Pérez-Vélez, C. M., ... & Cohen, T. (2014). Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. The Lancet, 383(9928), 1572–1579. https://doi.org/10.1016/S0140-6736(14)60195-1

Jassal, M., & Bishai, W. R. (2010). Extensively drug-resistant tuberculosis. The Lancet Infectious Diseases, 10(3), 159–170. https://doi.org/10.1016/S1473-3099(09)70330-3

World Health Organization. (2021). WHO Consolidated Guidelines on Tuberculosis. Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. WHO. Retrieved from https://www.who.int/publications/i/item/9789240028173

• PDF